Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Core Viewpoint - Plus Therapeutics Inc. announced a public offering priced at $0.38 per unit, aiming to raise approximately $15 million before expenses, which led to a decline in its stock price during trading sessions [1][2]. Group 1: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system [2]. - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [2]. Group 2: Financial and Market Performance - The stock closed at $0.47 on the previous trading day and was down 37.69% at $0.29 during premarket trading on Wednesday [2][7]. - The public offering is expected to close on January 15, 2026, with proceeds designated for working capital and general corporate purposes [2]. - Currently, shares are trading 47.7% below their 20-day simple moving average (SMA) and 48.3% below their 50-day SMA, indicating a bearish trend [5]. Group 3: Technical Indicators - The Relative Strength Index (RSI) stands at 36.82, suggesting neutral momentum, while the MACD is below its signal line, indicating bearish pressure on the stock [6]. - The combination of neutral RSI and bearish MACD suggests mixed momentum [6]. Group 4: Recent Developments - In January, Plus Therapeutics completed a Type B meeting with the U.S. FDA regarding the Reyobiq pivotal trial strategy for leptomeningeal metastases, intending to incorporate FDA feedback into the current dose optimization trial [3]. - In September 2025, CNSide Diagnostics, a subsidiary of Plus Therapeutics, signed a national agreement with UnitedHealthcare, covering over 51 million people in the U.S. for a laboratory-developed test [4].